geographic atrophy

News

winking smiley face on paper held in front of a woman's face

Astellas pulls geographic atrophy drug filing in the EU

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator.

News

Apellis will appeal CHMP’s rejection of pegcetacoplan

Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it dow

News

Astellas raises Padcev forecasts on bladder cancer data

Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new m

News

Novartis drops geographic atrophy gene therapy

Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer

News

Astellas' Iveric takeover rewarded with FDA nod for GA drug

The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company

News

Apellis slides on side effect reports with new eye drug

Apellis' share price came under pressure today after it revealed new details about a rare but serious side effect with its recently-approved Syfovre therapy for eye diseas

Astellas pulls geographic atrophy drug filing in the EU

Apellis will appeal CHMP’s rejection of pegcetacoplan

Astellas raises Padcev forecasts on bladder cancer data

Novartis drops geographic atrophy gene therapy

Astellas' Iveric takeover rewarded with FDA nod for GA drug

Apellis slides on side effect reports with new eye drug

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

geographic atrophy

Editor's Picks